Eptinezumab + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cluster Headache, Episodic
Conditions
Cluster Headache, Episodic
Trial Timeline
Dec 23, 2020 → Oct 5, 2023
NCT ID
NCT04688775About Eptinezumab + Placebo
Eptinezumab + Placebo is a phase 3 stage product being developed by Lundbeck for Cluster Headache, Episodic. The current trial status is completed. This product is registered under clinical trial identifier NCT04688775. Target conditions include Cluster Headache, Episodic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05897320 | Phase 3 | Recruiting |
| NCT05452239 | Approved | Completed |
| NCT04965675 | Phase 3 | Recruiting |
| NCT04688775 | Phase 3 | Completed |
| NCT04418765 | Phase 3 | Completed |
| NCT04336449 | Phase 1 | Completed |
| NCT04152083 | Phase 3 | Completed |
Competing Products
8 competing products in Cluster Headache, Episodic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Galcanezumab 300 mg + Placebo | Eli Lilly | Phase 3 | 77 |
| Galcanezumab | Eli Lilly | Phase 3 | 77 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| candesartan cilexetil + placebo | AstraZeneca | Phase 2 | 52 |
| SOM230 + Placebo | Novartis | Phase 2 | 52 |
| Bosutinib + Imatinib | Pfizer | Phase 3 | 76 |
| Eptinezumab | Lundbeck | Phase 3 | 74 |
| Methylprednisolone | Brain Biotech | Approved | 77 |